Skip to main content
. 2016 Oct 8;7(45):73912–73924. doi: 10.18632/oncotarget.12528

Table 2. Tissue uptake of 89Zr-Df-ATN-291 in different tumor-bearing mice (n = 4 for all tumor types, except LNCaP (n = 3)).

Tumor (%ID/g) Liver (%ID/g) Blood (%ID/g) Muscle (%ID/g) Tumor-to-muscle
2 h p.i.
DU-145 5.6 ± 1.6 11.6 ± 1.0 22.0 ± 3.8 0.7 ± 0.1 8.1 ± 3.1
BxPC-3 3.1 ± 0.4 17.5 ± 6.5 17.6 ± 1.0 0.9 ± 0.5 5.3 ± 4.4
MDA-MB-231 3.3 ± 1.0 21.0 ± 3.9 26.4 ± 5.1 1.1 ± 0.3 3.8 ± 2.4
SKOV-3 4.6 ± 1.4 18.4 ± 2.7 20.0 ± 5.2 1.1 ± 0.3 4.4 ± 0.2
LNCaP 1.0 ± 0.7 19.1 ± 2.4 25.2 ± 4.3 1.0 ± 0.3 1.5 ± 0.6
24 h p.i.
DU-145 15.3 ± 3.6 11.6 ± 2.5 13.4 ± 2.1 0.6 ± 0.2 26.6 ± 12.9
BxPC-3 9.4 ± 0.6 16.7 ± 6.8 9.2 ± 0.8 1.3 ± 0.3 7.4 ± 1.8
MDA-MB-231 11.7 ± 2.5 15.9 ± 2.6 12.7 ± 2.5 1.1 ± 0.5 9.4 ± 1.5
SKOV-3 10.8 ± 1.4 14.7 ± 0.4 11.3 ± 4.7 1.0 ± 0.3 9.2 ± 2.2
LNCaP 4.2 ± 1.5 18.4 ± 3.7 12.4 ± 2.1 1.2 ± 0.2 3.3 ± 0.8
72 h p.i.
DU-145 23.2 ± 2.8 12.1 ± 3.2 8.0 ± 0.9 0.5 ± 0.03 44.9 ± 4.8
BxPC-3 18.9 ± 1.9 16.4 ± 5.1 6.0 ± 1.2 1.1 ± 0.2 21.3 ± 3.8
MDA-MB-231 15.0 ± 1.3 16.0 ± 3.7 7.5 ± 1.8 1.5 ± 0.2 11.4 ± 2.1
SKOV-3 14.9 ± 3.5 14.7 ± 0.4 7.2 ± 3.0 1.3 ± 0.6 9.2 ± 2.4
LNCaP 7.5 ± 1.8 15.7 ± 3.6 6.4 ± 1.3 0.9 ± 0.3 8.9 ± 1.3
120 h p.i.
DU-145 25.4 ± 2.7 12.0 ± 3.2 4.7 ± 0.4 0.5 ± 0.05 47.9 ± 10.3
BxPC-3 22.6 ± 1.9 16.8 ± 6.1 4.6 ± 1.5 0.9 ± 0.3 25.3 ± 4.3
MDA-MB-231 16.5 ± 4.3 16.8 ± 4.3 4.9 ± 0.7 1.0 ± 0.4 13.4 ± 3.2
SKOV-3 15.2 ± 1.8 16.5 ± 2.6 4.5 ± 0.9 1.3 ± 0.4 10.1 ± 3.0
LNCaP 8.1 ± 1.5 12.4 ± 2.7 4.6 ± 1.2 0.9 ± 0.2 9.4 ± 1.2